KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares OutstandingShares Outstanding
Ratios

AbCellera Biologics (ABCL) Receivables Refunds (2020 - 2022)

AbCellera Biologics' Receivables Refunds history spans 3 years, with the latest figure at $64.8 million for Q4 2022.

  • For the quarter ending Q4 2022, Receivables Refunds rose 353.84% year-over-year to $64.8 million, compared with a TTM value of $64.8 million through Dec 2022, up 353.84%, and an annual FY2022 reading of $64.8 million, up 353.84% over the prior year.
  • Receivables Refunds for Q4 2022 was $64.8 million at AbCellera Biologics, up from $14.3 million in the prior quarter.
  • The five-year high for Receivables Refunds was $64.8 million in Q4 2022, with the low at $489000.0 in Q4 2020.
  • Average Receivables Refunds over 3 years is $26.5 million, with a median of $14.3 million recorded in 2021.
  • Year-over-year, Receivables Refunds soared 2820.65% in 2021 and then surged 353.84% in 2022.
  • Tracing ABCL's Receivables Refunds over 3 years: stood at $489000.0 in 2020, then soared by 2820.65% to $14.3 million in 2021, then surged by 353.84% to $64.8 million in 2022.
  • Per Business Quant, the three most recent readings for ABCL's Receivables Refunds are $64.8 million (Q4 2022), $14.3 million (Q4 2021), and $489000.0 (Q4 2020).